A phase II study of atezolizumab (atezo) with or without bevacizumab (bev) versus sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) patients (pts).
暂无分享，去创建一个
A. Ravaud | J. Hainsworth | R. Motzer | T. Powles | T. Choueiri | M. Atkins | M. Sznol | B. Rini | W. Stadler | B. Escudier | L. Fong | YounJeong Choi | S. Pal | G. Fine | R. Joseph | S. Bracarda | D. McDermott | C. Suarez | Thomas E. Hutson | M. Huseni